In last trading session, Regenxbio Inc (NASDAQ:RGNX) saw 0.74 million shares changing hands with its beta currently measuring 1.11. Company’s recent per share price level of $8.16 trading at -$0.53 or -6.10% at ring of the bell on the day assigns it a market valuation of $411.17M. That closing price of RGNX’s stock is at a discount of -88.24% from its 52-week high price of $15.36 and is indicating a premium of 38.36% from its 52-week low price of $5.03. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.58 million shares which gives us an average trading volume of 1.05 million if we extend that period to 3-months.
For Regenxbio Inc (RGNX), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.38. Splitting up the data highlights that, out of 6 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 6 see the stock as a Buy. 0 analyst(s) advised it as an Underweight.
Regenxbio Inc (NASDAQ:RGNX) trade information
Regenxbio Inc’s shares saw a change of -39.82% in year-to-date performance and have moved -5.99% in past 5-day. Regenxbio Inc (NASDAQ:RGNX) showed a performance of -5.77% in past 30-days. Number of shares sold short was 5.51 million shares which calculate 4.42 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 24 to the stock, which implies a rise of 66.0% to its current value. Analysts have been projecting 24 as a low price target for the stock while placing it at a high target of 24. It follows that stock’s current price would drop -194.12% in reaching the projected high whereas dropping to the targeted low would mean a loss of -194.12% for stock’s current value.
Regenxbio Inc (RGNX) estimates and forecasts
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -12.18% during past 5 years. In 2025, company’s earnings growth rate is likely to be around 93.62% while estimates for its earnings growth in next 5 years are of 22.89%.
Regenxbio Inc (NASDAQ:RGNX)’s Major holders
Insiders are in possession of 7.70% of company’s total shares while institution are holding 87.65 percent of that, with stock having share float percentage of 94.96%. Investors also watch the number of corporate investors in a company very closely, which is 87.65% institutions for Regenxbio Inc that are currently holding shares of the company. BLACKROCK INC. is the top institutional holder at RGNX for having 8.61 million shares of worth $100.73 million. And as of 2024-06-30, it was holding 17.0142 of the company’s outstanding shares.
The second largest institutional holder is VANGUARD GROUP INC, which was holding about 5.11 million shares on 2024-06-30. The number of shares represents firm’s hold over 10.1061 of outstanding shares, having a total worth of $59.83 million.
On the other hand, JPMorgan Trust II-JPMorgan Small Cap Growth Fund and VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund are the top two Mutual Funds which own company’s shares. As of Mar 31, 2025 , the former fund manager was holding 1.98 shares of worth $16.13 million or 3.92% of the total outstanding shares. The later fund manager was in possession of 1.4 shares on Mar 31, 2025 , making its stake of worth around $11.43 million in the company or a holder of 2.78% of company’s stock.
